SOUTH KOREA · OPENDART
Penetrium Bioscience Inc.
페니트리움바이오 · 187660 · KOSDAQ · Healthcare · Medical Care Facilities
Score
41.6
Insider timeline
One insider bought, once (26 Aug). The share closed at 3,850.00 that day and at 5,830.00 most recently (+51.4%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
Blue line: this share's price, −52.8% over these six months
The closing price of each day, from 12,350.00 on 2026-04-21 to 5,830.00 on 2026-10-16. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −31.9%
Taken from the 1525 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −52.8%, the typical one −31.9%, 20.9 points behind. It is not an index and not a comparison within one industry.
This company: insiders buying per month, last 12 months
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| CHA SEUK PARK | Board member | 1 | — | 2.7M KRW | 2026-08-26 | +51.4% |
Insiders' buying price vs the latest close
Insiders paid 2,997.22 KRW a share on average (3 purchase lines, 2 buyers, 2025-10-21 – 2026-08-26). The close on 2026-10-16 was 94.5% above that price.
The latest purchase (2026-08-26) was at 3,865.00 KRW; the close was 50.8% above that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
| Trade date | Insider | Role | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-26 | CHA SEUK PARK | Audit committee member | Bought on the exchange | 692 | ₩3,865 | ₩2.7M | DART ↗ |
| 2025-11-10 | Park Cha-seok | Outside director | Bought on the exchange | 8,900 | ₩2,720 | ₩24.2M | DART ↗ |
| 2025-10-21 | Park Cha-seok | Outside director | Bought on the exchange | 10,500 | ₩3,175 | ₩33.3M | DART ↗ |
Other changes in holdings · 14
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.
| Date | Insider | Role | Reason | Shares | Filing |
|---|---|---|---|---|---|
| 2026-08-28 | HYUNDAI BIOSCIENCE CO., LTD. | 10% shareholder | Acquisition of paid-in new shares(+) | 2,233,264 | DART ↗ |
| 2026-08-28 | CHA SEUK PARK | Audit committee member | Acquisition of paid-in new shares(+) | 9,308 | DART ↗ |
| 2026-08-19 | CHA SEUK PARK | Audit committee member | Donation(-) | 10,000 | DART ↗ |
| 2026-08-19 | CHA SEUK PARK | Audit committee member | Donation(-) | 0 | DART ↗ |
| 2026-02-06 | PARK CHA SEUK | Audit committee member | Acquisition in exchange(+) | 5,600 | DART ↗ |
| 2026-02-06 | PARK CHA SEUK | Audit committee member | Acquisition in exchange(+) | 0 | DART ↗ |
| 2025-12-12 | Park Cha-seok | Outside director | Acquisition in exchange(+) | 15,000 | DART ↗ |
| 2025-12-12 | Park Cha-seok | Outside director | Acquisition in exchange(+) | 0 | DART ↗ |
| 2025-11-12 | Park Cha-seok | Outside director | Acquisition in exchange(+) | 0 | DART ↗ |
| 2025-11-05 | HYUNDAI BIOSCIENCE CO., LTD. | 10% shareholder | Conversion, etc.(-) | 1,146,226 | DART ↗ |
| 2025-10-27 | HYUNDAI BIOSCIENCE CO., LTD. | 10% shareholder | CB acquisition(+) | 1,146,226 | DART ↗ |
| 2025-07-31 | PARK CHA SEUK | Audit committee member | New appointment(+) | 10,000 | DART ↗ |
| 2024-11-28 | HYUNDAI BIOSCIENCE CO., LTD. | 10% shareholder | Acquisition of new shares without compensation(+) | 6,623,641 | DART ↗ |
| 2011-11-05 | HYUNDAI BIOSCIENCE CO., LTD. | 10% shareholder | Exercise of convertible bond rights(+) | 1,146,226 | DART ↗ |